These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20733094)

  • 1. Predictors of early discontinuation of dual-antiplatelet therapy: room for improvement.
    Jarvie JL; Foody JM
    Circulation; 2010 Sep; 122(10):946-8. PubMed ID: 20733094
    [No Abstract]   [Full Text] [Related]  

  • 2. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
    Ferreira-González I; Marsal JR; Ribera A; Permanyer-Miralda G; García-Del Blanco B; Martí G; Cascant P; Martín-Yuste V; Brugaletta S; Sabaté M; Alfonso F; Capote ML; De La Torre JM; Ruíz-Lera M; Sanmiguel D; Cárdenas M; Pujol B; Baz JA; Iñiguez A; Trillo R; González-Béjar O; Casanova J; Sánchez-Gila J; García-Dorado D
    Circulation; 2010 Sep; 122(10):1017-25. PubMed ID: 20733100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting coronary artery stents.
    Dehmer GJ; Smith KJ
    Am Fam Physician; 2009 Dec; 80(11):1245-51. PubMed ID: 19961137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
    Ducrocq G; Serebruany V; Tanguay JF
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stent thrombosis.
    Stähli BE; Camici GG; Tanner FC
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):45-52. PubMed ID: 19124388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Chhatriwalla AK; Bhatt DL
    Circ Cardiovasc Interv; 2008 Dec; 1(3):217-25. PubMed ID: 20031681
    [No Abstract]   [Full Text] [Related]  

  • 7. Status of drug-eluting coronary stents.
    Chodosh A; Korr KS; Burtt D
    Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based management of patients undergoing PCI: stent controversies.
    Vetrovec GW
    Catheter Cardiovasc Interv; 2010 Mar; 75 Suppl 1():S39-42. PubMed ID: 20333706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.
    Rossini R; Musumeci G; Aprile A; Valsecchi O
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):49-61. PubMed ID: 20121564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
    Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
    Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges of antiplatelet therapy in patients who require anticoagulation.
    Henkel DM; Holmes DR
    J Invasive Cardiol; 2009 Apr; 21(4):186-9. PubMed ID: 19342758
    [No Abstract]   [Full Text] [Related]  

  • 12. [Percutaneous coronary intervention].
    Csapó K
    Orv Hetil; 2005 Mar; 146(13):587-93. PubMed ID: 15856622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    Baber U; Akhter M; Kothari S; Sharma SK; Kini A
    J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on drug-eluting stents.
    Sims JM
    Dimens Crit Care Nurs; 2007; 26(6):237-40. PubMed ID: 18090139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention.
    Tan VP; Yan BP; Kiernan TJ; Ajani AE
    Cardiovasc Revasc Med; 2009; 10(1):36-44. PubMed ID: 19159853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
    Kumbhani DJ; Bavry AA; Bhatt DL
    Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study.
    Zhu ZB; Zhang RY; Zhang Q; Zhang JS; Hu J; Yang ZK; Shen WF
    Cardiology; 2009; 112(3):191-9. PubMed ID: 18682662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying drug-eluting stents in clinical practice.
    King SB
    Am J Cardiol; 2007 Sep; 100(5A):25K-31K. PubMed ID: 17719350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use and the spectre of drug-eluting stent thrombosis.
    Cook S; Wenaweser P
    Circ Cardiovasc Interv; 2009 Aug; 2(4):273-6. PubMed ID: 20031728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.